Dr Shamith Samarajiwa

University of Cambridge

University departments
MRC Cancer Unit
University institutes
Hutchison MRC Research Centre

Position: Group Leader
Personal home page: https://www.samarajiwa-lab.org/

PubMed journal articles - click here

Dr Shamith Samarajiwa is pleased to consider applications from prospective PhD students.

Research description

My lab develops multi-disciplinary data science, data engineering and computational biology solutions to understand multi-scale biological systems involved in immunity, inflammation and cancer. We are particularly interested in understanding complex systems underlying tumorigenesis and early carcinogenesis, and interactions between the immune system and cancer. We have expertise in data integration and are currently developing and applying AI technologies for early detection of cancer.

https://scholar.google.co.uk/citations?user=vUsVyRUAAAAJ

Research Programme
Early Detection
Methods and technologies
Bioinformatics
Computational modelling
DNA sequencing
Gene expression profiling
Genomics
Microarray
Proteomics
Statistical analysis
Tumour type interests
Brain and central nervous system
Breast
Colorectal
Kidney
Leukemia
Lung
Oesophagus
Ovary
Pancreas
Prostate
Keywords

Computational Biology
Artificial Intelligence
Data Science
Genomics

ss861
Recent publications:
 Retrieving latest data from feed...

Symplectic Elements feed provided by Research Information, University of Cambridge


Key publications

Phenotype specific analyses reveal distinct regulatory mechanism for chronically activated p53. Kirschner K*, Samarajiwa SA*, Cairns JM, Menon S, Pérez-Mancera PA, Tomimatsu K, Bermejo-Rodriguez C, Ito Y, Chandra T, Narita M, Lyons SK, Lynch AG, Kimura H, Ohbayashi T, Tavaré S, Narita M. PLoS Genet. 2015 Mar

Spatial coupling of mTOR and autophagy augments secretory phenotypes.
Narita M*, Young AR*, Arakawa S, Samarajiwa SA, Nakashima T, Yoshida S, Hong S,
Berry LS, Reichelt S, Ferreira M, Tavaré S, Inoki K, Shimizu S, Narita M. Science. 2011 May
20;332(6032):966-70.

INTERFEROME: the database of interferon regulated genes.
Samarajiwa SA*, Forster S, Auchettl K, Hertzog PJ. Nucleic Acids Res. 2009 Jan;37:D852-7.

Soluble IFN receptor potentiates in vivo type I IFN signaling and exacerbates TLR4-mediated septic shock. Samarajiwa SA, Mangan NE, Hardy MP, Najdovska M, Dubach D, Braniff SJ, Owczarek CM, Hertzog PJ. J Immunol. 2014 May 1;192(9):4425-35. doi: 10.4049/jimmunol.1302388.

Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, Andrews D, Mikeska T, Mangan NE, Samarajiwa SA, de Weerd NA, Gould J, Argani P, Möller A, Smyth MJ, Anderson RL, Hertzog PJ, Parker BS. Nat Med. 2012 Aug;18(8):1224-31. doi: 10.1038/nm.2830.

Independence of repressive histone marks and chromatin compaction during senescent heterochromatic layer formation. Chandra T, Kirschner K, Thuret JY, Pope BD, Ryba T, Newman S, Ahmed K, Samarajiwa SA, Salama R, Carroll T, Stark R, Janky R, Narita M, Xue L, Chicas A, Nũnez S, Janknecht R, Hayashi-Takanaka Y, Wilson MD, Marshall A, Odom DT, Babu MM, Bazett-Jones DP, Tavaré S, Edwards PA, Lowe SW, Kimura H, Gilbert DM, Narita M. Mol Cell. 2012 Jul 27;47(2):203-14. doi: 10.1016/j.molcel.2012.06.010.

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Gräf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S; METABRIC Group, Langerød A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Børresen-Dale AL, Brenton JD, Tavaré S, Caldas C, Aparicio S. Nature. 2012 Apr 18;486(7403):346-52. doi: 10.1038/nature10983.